Meningitis vaccine to be offered to thousands across England after deadly Kent outbreak

The UK government has announced a one-off MenB vaccination campaign targeting Year 13 pupils and under-25s entering university or residential further education for the first time this autumn. The move follows an unprecedented meningitis outbreak in Kent earlier this year, which became the fastest-growing and largest MenB outbreak ever recorded in the UK, with 21 confirmed cases and two deaths, including an 18-year-old Faversham schoolgirl, Juliette Kenny, and a University of Kent student. The campaign will offer two doses of the MenB vaccine to eligible students ahead of the academic year, aiming to reduce the risk of serious illness and further outbreaks. Eligible Year 13 pupils were born between September 1, 2007, and August 31, 2008, regardless of their higher education plans. Under-25s starting university or certain residential further education settings for the first time will also qualify. Health Secretary James Murray stated that the Kent outbreak and recent clusters suggest a possible change in how MenB affects people. He emphasized the need to protect young people at highest immediate risk, noting that the vaccine rollout will help prevent preventable deaths. The Department of Health confirmed that the campaign is a one-off measure, despite calls from local figures like Louise Jones-Roberts, owner of Canterbury’s Club Chemistry, which was linked to several cases, for a rolling program. The outbreak in Kent led to one of the largest public health responses in recent years, with 34 hospitalizations at its peak. Thousands of students, school pupils, and close contacts received emergency vaccinations and precautionary antibiotics. MenB, a rare but life-threatening bacterial infection, can cause meningitis and sepsis, with a fatality rate of around one in 10 cases and potential life-changing injuries for survivors. Local medical professionals, including Medway GP Dr Julian Spinks, welcomed the vaccination program but raised concerns about logistical challenges, particularly delivering the second dose during the summer holidays. Dr Spinks described the outbreak’s scale and speed as shocking, highlighting the rapid deterioration of patients and the critical need for public awareness of symptoms. The campaign aims to mitigate future risks while health authorities assess the latest evidence on MenB’s evolving impact on young people.